Description: Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Home Page: www.exelixis.com
EXEL Technical Analysis
1851 Harbor Bay Parkway
Alameda,
CA
94502
United States
Phone:
650 837 7000
Officers
| Name | Title |
|---|---|
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board |
| Dr. Michael M. Morrissey Ph.D. | CEO, Pres & Director |
| Mr. Christopher J. Senner | Exec. VP & CFO |
| Dr. Peter Lamb Ph.D. | Exec. VP of Scientific Strategy & Chief Scientific Officer |
| Mr. Jeffrey J. Hessekiel J.D. | Exec. VP, Gen. Counsel & Sec. |
| Mr. Patrick J. Haley M.B.A., MBA | Exec. VP of Commercial |
| Dr. Dana T. Aftab Ph.D. | Exec. VP of Bus. Operations |
| Ms. Susan T. Hubbard | Exec. VP of Public Affairs & Investor Relations |
| Mr. Gregg Bernier | VP of Marketing |
| Ms. Laura Dillard | Exec. VP of HR |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 10.582 |
|---|---|
| Trailing PE: | 17.0202 |
| Price-to-Book MRQ: | 2.0417 |
| Price-to-Sales TTM: | 3.1109 |
| IPO Date: | 2000-04-07 |
| Fiscal Year End: | January |
| Full Time Employees: | 954 |